FINI, ELISABETTA Statistiche
FINI, ELISABETTA
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
2023-01-01 Convertino, I.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Giometto, S.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Bonaso, M.; Blandizzi, C.; Tuccori, M.; Lucenteforte, E.
Methadone dose escalation in patients with opioid use disorder and cancer as a strategy for controlling cancer-related pain: A case series
2023-01-01 Carli, Marco; Fini, Elisabetta; DE LUCA, Giulia; Scarselli, Marco; Lamanna, Francesco; Vico, Tiziana; Bocci, Guido
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
2022-01-01 Coltelli, L.; Allegrini, G.; Orlandi, P.; Finale, C.; Fontana, A.; Masini, L. C.; Scalese, M.; Arrighi, G.; Barletta, M. T.; De Maio, E.; Banchi, M.; Fini, E.; Guidi, P.; Frenzilli, G.; Donati, S.; Giovannelli, S.; Tanganelli, L.; Salvadori, B.; Livi, L.; Meattini, I.; Pazzagli, I.; Di Lieto, M.; Pistelli, M.; Casadei, V.; Ferro, A.; Cupini, S.; Orlandi, F.; Francesca, D.; Lorenzini, G.; Barellini, L.; Falcone, A.; Cosimi, A.; Bocci, G.
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer
2022-01-01 Fornaro, L.; Musettini, G.; Orlandi, P.; Pecora, I.; Vivaldi, C.; Banchi, M.; Salani, F.; Fini, E.; Massa, V.; Catanese, S.; Cucchiara, F.; Lencioni, M.; Masi, G.; Vasile, E.; Bocci, G.
Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
2022-01-01 Banchi, Marta; Fini, Elisabetta; Crucitta, Stefania; Bocci, Guido
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future
2021-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D.
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO
2021-01-01 Valdiserra, G.; Convertino, I.; Giometto, S.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Blandizzi, C.; Lucenteforte, E.; Tuccori, M.
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study
2021-01-01 Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study
2021-01-01 Tuccori, M; Lorenzoni, V; Gini, R; Turchetti, G; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma
2020-01-01 Orlandi, Paola; Banchi, Marta; Alì, Greta; Di Desidero, Teresa; Fini, Elisabetta; Fontanini, Gabriella; Bocci, Guido
Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer
2020-01-01 Banchi, Marta; Orlandi, Paola; Gentile, Daniela; Alì, Greta; Fini, Elisabetta; Fontanini, Gabriella; Francia, Giulio; Bocci, Guido
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis | 1-gen-2023 | Convertino, I.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Giometto, S.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Bonaso, M.; Blandizzi, C.; Tuccori, M.; Lucenteforte, E. | |
| Methadone dose escalation in patients with opioid use disorder and cancer as a strategy for controlling cancer-related pain: A case series | 1-gen-2023 | Carli, Marco; Fini, Elisabetta; DE LUCA, Giulia; Scarselli, Marco; Lamanna, Francesco; Vico, Tiziana; Bocci, Guido | |
| A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients | 1-gen-2022 | Coltelli, L.; Allegrini, G.; Orlandi, P.; Finale, C.; Fontana, A.; Masini, L. C.; Scalese, M.; Arrighi, G.; Barletta, M. T.; De Maio, E.; Banchi, M.; Fini, E.; Guidi, P.; Frenzilli, G.; Donati, S.; Giovannelli, S.; Tanganelli, L.; Salvadori, B.; Livi, L.; Meattini, I.; Pazzagli, I.; Di Lieto, M.; Pistelli, M.; Casadei, V.; Ferro, A.; Cupini, S.; Orlandi, F.; Francesca, D.; Lorenzini, G.; Barellini, L.; Falcone, A.; Cosimi, A.; Bocci, G. | |
| Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer | 1-gen-2022 | Fornaro, L.; Musettini, G.; Orlandi, P.; Pecora, I.; Vivaldi, C.; Banchi, M.; Salani, F.; Fini, E.; Massa, V.; Catanese, S.; Cucchiara, F.; Lencioni, M.; Masi, G.; Vasile, E.; Bocci, G. | |
| Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies | 1-gen-2022 | Banchi, Marta; Fini, Elisabetta; Crucitta, Stefania; Bocci, Guido | |
| An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future | 1-gen-2021 | Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D. | |
| Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO | 1-gen-2021 | Valdiserra, G.; Convertino, I.; Giometto, S.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Blandizzi, C.; Lucenteforte, E.; Tuccori, M. | |
| Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study | 1-gen-2021 | Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G | |
| Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study | 1-gen-2021 | Tuccori, M; Lorenzoni, V; Gini, R; Turchetti, G; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E | |
| Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma | 1-gen-2020 | Orlandi, Paola; Banchi, Marta; Alì, Greta; Di Desidero, Teresa; Fini, Elisabetta; Fontanini, Gabriella; Bocci, Guido | |
| Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer | 1-gen-2020 | Banchi, Marta; Orlandi, Paola; Gentile, Daniela; Alì, Greta; Fini, Elisabetta; Fontanini, Gabriella; Francia, Giulio; Bocci, Guido |